HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

I Virgolini Selected Research

I Virgolini Research Topics

Disease

13Neoplasms (Cancer)
01/2014 - 03/2000
4Thyroid Neoplasms (Thyroid Cancer)
04/2019 - 01/2002
4Neoplasm Metastasis (Metastasis)
02/2010 - 12/2000
4Neuroendocrine Tumors (Neuroendocrine Tumor)
01/2002 - 01/2001
3Lymphoma (Lymphomas)
01/2012 - 09/2001
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2002 - 06/2001
2Adenocarcinoma
02/2002 - 03/2001
2Carcinoma (Carcinomatosis)
02/2002 - 02/2001
2Lung Neoplasms (Lung Cancer)
01/2002 - 09/2001
2Liver Neoplasms (Liver Cancer)
01/2002 - 06/2000
1Squamous Cell Carcinoma of Head and Neck
12/2012
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2012
1Hodgkin Disease (Hodgkin's Disease)
01/2012
1Nausea
02/2002
1Weight Gain
02/2002
1Pancreatic Neoplasms (Pancreatic Cancer)
12/2001
1Familial primary gastric lymphoma
11/2001
1Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
11/2001
1Burkitt Lymphoma (Burkitt's Lymphoma)
05/2001
1Colorectal Neoplasms (Colorectal Cancer)
03/2001
1Disease Progression
06/2000
1Carcinoid Tumor (Carcinoid)
03/2000

Drug/Important Bio-Agent (IBA)

9Somatostatin Receptors (Somatostatin Receptor)IBA
01/2014 - 06/2001
8Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
01/2014 - 03/2000
7lanreotide (Somatuline)FDA Link
02/2002 - 03/2000
51,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
02/2010 - 03/2000
4Peptides (Polypeptides)IBA
01/2014 - 03/2000
4Radioisotopes (Radionuclides)IBA
07/2011 - 01/2001
3Peptide Receptors (Peptide Receptor)IBA
07/2011 - 03/2000
3Octreotide (Sandostatin)FDA LinkGeneric
01/2002 - 03/2000
3indium 111-DOTA-lanreotideIBA
09/2001 - 01/2001
2RadiopharmaceuticalsIBA
04/2019 - 03/2000
2Glucose (Dextrose)FDA LinkGeneric
01/2012 - 12/2000
2AcidsIBA
12/2001 - 09/2001
2LigandsIBA
12/2001 - 05/2001
2Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA
03/2001 - 02/2001
1IodineIBA
01/2015
1somatostatin receptor 2IBA
01/2014
1somatostatin receptor 5IBA
12/2012
1Chromogranin AIBA
12/2012
1SynaptophysinIBA
12/2012
1FluorineIBA
01/2012
1gallium 68-DOTA-lanreotideIBA
02/2010
1serum P-component (CIt)IBA
02/2010
13-Tyr-octreotideIBA
09/2005
1EDDA (NiEDDA)IBA
09/2005
1CamptothecinIBA
12/2001
1Cisplatin (Platino)FDA LinkGeneric
12/2001
1Doxorubicin (Adriamycin)FDA LinkGeneric
12/2001
1GemcitabineFDA Link
12/2001
1Fluorouracil (Carac)FDA LinkGeneric
12/2001
1Mitomycin (Mitomycin-C)FDA LinkGeneric
12/2001
1yttrium 90-DOTA-lanreotideIBA
06/2001
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
05/2001
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2001
1Interferon-alpha (Interferon Alfa)IBA
05/2001
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2001
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
03/2001
1oxidized low density lipoproteinIBA
02/2001
1LDL Lipoproteins (beta Lipoproteins)IBA
02/2001
1LDL Receptors (LDL Receptor)IBA
02/2001
1Lipoprotein Receptors (Lipoprotein Receptor)IBA
02/2001
1Lipoproteins (Lipoprotein)IBA
02/2001

Therapy/Procedure

11Therapeutics
04/2019 - 01/2001
1Intravenous Injections
02/2010
1Drug Therapy (Chemotherapy)
02/2002
1Intramuscular Injections
06/2000